Table 6.
Targeted drugs and clinical trials related to PD-1
| Drug | Disease | Trial name | Phase | Status | ORR/CR | NCT# | Reference |
|---|---|---|---|---|---|---|---|
| Nivolumab | A human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2 | ||||||
| Nivolumab | Relapsed or refractory HL | PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma | 1 | Completed | 87%/17% | NCT01592370 | 349 |
| Nivolumab | Relapsed or refractory HL | Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicenter, multicohort, single-arm phase 2 trial | 2 | Completed | 66.3%/9% | NCT02181738 | 350 |
| Nivolumab | Relapsed or refractory NHLs/MM | Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase 1 study | 1 | Completed | FL, 40%/10%; DLBCL, 36%/18%; T-NHLs, 17%/0% | NCT01592370 | 386 |
| Nivolumab | Relapsed or refractory DLBCL (failed or not eligible for ASCT) | Study of nivolumab in patients with relapsed or refractory diffuse large B-cell lymphoma that have either failed or are not eligible for autologous stem cell transplant | 2 | Completed | ASCT-failed, 10.3%/2.9%; ASCT ineligible, 3.4%/0% | NCT02038933 | – |
| Nivolumab | Relapsed or refractory ALK+ ALCL | Phase 2 trial of nivolumab for pediatric and adult relapsed or refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (cohort 2) | 2 | Recruiting | – | NCT03703050 | – |
| Nivolumab | Relapsed or refractory PTCL | Nivolumab in treating patients with relapsed or refractory peripheral T-cell lymphoma | 2 | Active, not recruiting | – | NCT03075553 | – |
| Nivolumab | Relapsed or refractory PCNSL/primary testicular lymphoma | PD-1 blockade with nivolumab in relapsed or refractory primary central nervous system and testicular lymphoma | 2 | Completed | 100%/80% | NCT02857426 | 351 |
| Nivolumab, BV | Relapsed or refractory HL | Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin’s lymphoma | 1/2 | Completed | 82%/61% | NCT02572167 | 387 |
| Nivolumab, BV | NHLs | An investigational immunotherapy effectiveness and safety study of nivolumab in combination with brentuximab vedotin to treat non-Hodgkin’s lymphomas | 1/2 | Active, not recruiting | – | NCT02581631 | – |
| Nivolumab, lenalidomide | Relapsed or refractory NHLs/HL | Nivolumab and lenalidomide in treating patients with relapsed or refractory non-Hodgkin’s or Hodgkin’s lymphoma | 1/2 | Recruiting | – | NCT03015896 | – |
| Nivolumab, rituximab | FL | Nivolumab plus rituximab in first-line follicular lymphoma grade 1-3A | 1 | Recruiting | – | NCT03245021 | – |
| Nivolumab, cabiralizumab | PTCL | Nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab in patients with relapsed or refractory peripheral T-cell lymphoma | 2 | Recruiting | – | NCT03927105 | – |
| Nivolumab, rituximab, gemcitabine, oxaliplatin | NHLs (elderly patients) | Nivolumab with gemcitabine, oxaliplatin, rituximab in relapsed or refractory elderly lymphoma patients | 2/3 | Recruiting | – | NCT03366272 | – |
| Nivolumab, R-CHOP | Aggressive NHLs | Nivolumab and combination chemotherapy in treating participants with diffuse large B-cell lymphoma | 1/2 | Recruiting | – | NCT03704714 | – |
| Nivolumab, DA-R-EPOCH | Aggressive NHLs | Nivolumab with DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin’s lymphoma | 2 | Recruiting | – | NCT03749018 | – |
| Pembrolizumab | A humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2 | ||||||
| Pembrolizumab | Relapsed or refractory HL | PD-1 blockade with pembrolizumab in patients with classical Hodgkin’s lymphoma after brentuximab vedotin failure | 1 | Completed | 65%/16% | NCT01953692 | 353 |
| Pembrolizumab | Relapsed or refractory HL | Phase 2 study of the efficacy and safety of pembrolizumab for relapsed or refractory classic Hodgkin’s lymphoma | 2 | Completed | 69%/22.4% | NCT02453594 | 366 |
| Pembrolizumab | Transformed DLBCL/relapsed or refractory CLL | Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL | 2 | Completed | transformed DLBCL, 41%/11%; CLL, 0%/0% | NCT02332980 | 388 |
| Pembrolizumab | Relapsed or refractory PMBCL | Safety and tolerability of pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma | 1 | Completed | 41%/11.8% | NCT01953692 | 389 |
| Pembrolizumab | Relapsed or refractory GZL/extranodal DLBCL | Pembrolizumab in relapsed or refractory gray-zone lymphoma, primary central nervous system lymphoma, and other extranodal diffuse large B-cell lymphomas | 2 | Recruiting | – | NCT03255018 | – |
| Pembrolizumab | Untreated B-NHLs | Pembrolizumab in untreated B-cell non-Hodgkin’s lymphoproliferative diseases | 2 | Recruiting | – | NCT03498612 | – |
| Pembrolizumab | Relapsed or refractory stage IB-IVB MF/SS | A phase 2 study of pembrolizumab for the treatment of relapsed or refractory mycosis fungoides/Sézary syndrome | 2 | Completed | 37.5%/8.3% | NCT02243579 | – |
| Pembrolizumab | Stage IB-IV MF | Pembrolizumab in treating patients with stage IB-IV mycosis fungoides | 2 | Recruiting | – | NCT03695471 | – |
| Pembrolizumab | Early stage NKTCL, nasal type | Study of pembrolizumab in patients with early stage NK/T-Cell lymphoma, nasal type | 2 | Recruiting | – | NCT03728972 | – |
| Pembrolizumab, umbralisib | Relapsed or refractory B-NHLs/CLL | Combination of pembrolizumab with umbralisib in patients with relapsed or refractory CLL and B-NHLs | 1 | Recruiting | – | NCT03283137 | – |
| Pembrolizumab, lenalidomide | Relapsed NHLs/HL | Efficacy and safety study of combination of pembrolizumab and lenalidomide, in patients with relapsed non-Hodgkin’s and Hodgkin’s lymphoma | 1/2 | Active, not recruiting | – | NCT02875067 | – |
| Pembrolizumab, mogamulizumab | Relapsed or refractory NHLs/HL | Pembrolizumab and mogamulizumab in treating patients with relapsed or refractory lymphomas | 1/2 | Recruiting | – | NCT03309878 | – |
| Pembrolizumab, rituximab | Relapsed or refractory DLBCL/FL | Pembrolizumab and rituximab in treating patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma | 2 | Recruiting | – | NCT03401853 | – |
| Pralatrexate | Relapsed or refractory mature T- and NK-cell NHLs/MF | Pembrolizumab and pralatrexate in treating participants with relapsed or refractory peripheral T-cell lymphoma | 1/2 | Recruiting | – | NCT03598998 | – |
| Pembrolizumab, tisagenlecleucel | Relapsed or refractory DLBCL | Study of pembrolizumab in combination with tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma patients | 1 | Recruiting | – | NCT03630159 | – |
| Pembrolizumab, EBRT | Relapsed or refractory NHLs | Pembrolizumab and external beam radiation therapy in treating participants with relapsed or refractory non-Hodgkin lymphomas | 2 | Recruiting | – | NCT03210662 | – |
| Pembrolizumab, radiotherapy | Relapsed or refractory MF/SS | A trial assessing the effect of pembrolizumab combined with radiotherapy in patients with relapsed or refractory, specified stages of cutaneous T-cell lymphoma mycosis fungoides/Sézary syndrome (PORT) | 2 | Recruiting | – | NCT03385226 | – |
NA: ORR or CR are not available on the clinicaltrials.gov or from the published article although the trial has been completed
BV brentuximab vedotin, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, DA-R-EPOCH rituximab, dose-adjusted EPOCH, GZL gray-zone lymphoma, EBRT external beam radiotherapy